Our top pick for
Fate Therapeutics, Inc is a biotechnology business based in the US. Fate Therapeutics shares (FATE) are listed on the NASDAQ and all prices are listed in US Dollars. Fate Therapeutics employs 178 staff and has a trailing 12-month revenue of around USD$13.2 million.
Since the stock market crash in March caused by coronavirus, Fate Therapeutics's share price has had significant positive movement.
Its last market close was USD$52.8, which is 41.40% up on its pre-crash value of USD$30.94 and 215.22% up on the lowest point reached during the March crash when the shares fell as low as USD$16.75.
If you had bought USD$1,000 worth of Fate Therapeutics shares at the start of February 2020, those shares would have been worth USD$821.46 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,946.74.
|Latest market close||USD$52.8|
|52-week range||USD$13.26 - USD$51.1|
|50-day moving average||USD$39.1338|
|200-day moving average||USD$33.5707|
|Wall St. target price||USD$39.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.222|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-23)||-2.74%|
|1 month (2020-10-30)||18.92%|
|3 months (2020-08-28)||46.75%|
|6 months (2020-05-29)||62.81%|
|1 year (2019-11-29)||238.03%|
|2 years (2018-11-30)||243.75%|
|3 years (2017-11-30)||1,100.00%|
|5 years (2015-11-30)||1,160.14%|
|Revenue TTM||USD$13.2 million|
|Gross profit TTM||USD$-77,090,000|
|Return on assets TTM||-17.49%|
|Return on equity TTM||-38.73%|
|Market capitalisation||USD$4.1 billion|
TTM: trailing 12 months
There are currently 13.9 million Fate Therapeutics shares held short by investors – that's known as Fate Therapeutics's "short interest". This figure is 7.6% up from 12.9 million last month.
There are a few different ways that this level of interest in shorting Fate Therapeutics shares can be evaluated.
Fate Therapeutics's "short interest ratio" (SIR) is the quantity of Fate Therapeutics shares currently shorted divided by the average quantity of Fate Therapeutics shares traded daily (recently around 1.1 million). Fate Therapeutics's SIR currently stands at 12.62. In other words for every 100,000 Fate Therapeutics shares traded daily on the market, roughly 12620 shares are currently held short.
However Fate Therapeutics's short interest can also be evaluated against the total number of Fate Therapeutics shares, or, against the total number of tradable Fate Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Fate Therapeutics's short interest could be expressed as 0.16% of the outstanding shares (for every 100,000 Fate Therapeutics shares in existence, roughly 160 shares are currently held short) or 0.2235% of the tradable shares (for every 100,000 tradable Fate Therapeutics shares, roughly 224 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Fate Therapeutics.
Find out more about how you can short Fate Therapeutics stock.
We're not expecting Fate Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Fate Therapeutics's shares have ranged in value from as little as $13.26 up to $51.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Fate Therapeutics's is 1.5654. This would suggest that Fate Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development includes FT516 for the treatment of acute myeloid leukemia (AML) and B-cell lymphoma, FT596 to treat B-cell lymphoma and CLL, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT819 to treat B-cell malignancies, and FT-ONO1 to treat hematologic malignancies; and FT500, FT516, and FT-ONO2 for the treatment of advanced solid tumors. The company's NK- and T-cell immuno-oncology programs under development also includes ProTmune for the treatment of hematologic malignancies; FATE-NK100 for the treatment of recurrent ovarian cancer; and FATE-NK100 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.